Alzheimer Disease Biomarkers and New Disease Modifying Treatments

Michael Borrie, MB ChB, FRCPC is a Geriatrician and Professor in the Department of Medicine, Division of Geriatric Medicine, The University of Western Ontario.

He is the Medical Director for the Aging Brain and Memory Clinic, an investigator with the Cognitive Clinical Research Group (CCRG), Past President of the Consortium for Canadian Centres for Clinical Cognitive Research (C5R).

His research interests include investigator-initiated studies for predictors of conversion from mild cognitive impairment (MCI) to Alzheimer Disease (AD), including sensitive neuroimaging techniques, blood and cerebral spinal fluid biomarkers. He is the platform lead for the Comprehensive Assessment of Neurodegeneration and Aging (COMPASS-ND) observational study of the Canadian Collaboration on Neurodegeneration in Aging (CCNA).

Since 1995 the CCRG has been a leading Canadian research site conducting randomized controlled trials of new potential treatments for Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer’s disease.